Ornithine is a non-proteinogenic amino acid (it is not one of the 20 standard amino acids that are incorporated into proteins) that is a critical intermediate in the urea cycle — the cycle of biochemical reactions that converts the toxic nitrogen waste products of protein metabolism (ammonia) into urea, which is then safely excreted in the urine. Ornithine is essential for the function of the urea cycle — it is the carrier of the nitrogen atoms that are added to the urea molecule at two points in the cycle, and it is the substrate for the enzyme ornithine transcarbamylase (OTC), which is the second enzyme of the urea cycle and one of the most critical enzymes in nitrogen metabolism. Without adequate ornithine, the urea cycle cannot function, ammonia accumulates in the blood and tissues, and hyperammonemia develops — a condition that is rapidly fatal if untreated and that is one of the most acute medical emergencies in clinical medicine. The neurological manifestations of hyperammonemia (lethargy, confusion, seizures, coma, and cerebral oedema) are the direct result of the toxic effects of ammonia on the brain.
The Urea Cycle and Its Clinical Significance
The urea cycle operates in two cellular compartments — the mitochondrial phase and the cytoplasmic phase. In the mitochondrial phase, ammonia (generated from the deamination of amino acids in the liver) is combined with bicarbonate and ATP to form carbamoyl phosphate by the enzyme carbamoyl phosphate synthetase I (CPS1, the first and rate-limiting enzyme of the urea cycle). The carbamoyl phosphate is then combined with ornithine to form citrulline (catalysed by ornithine transcarbamylase, OTC), and the citrulline is transported to the cytoplasm. In the cytoplasmic phase, citrulline is combined with aspartate (which provides the second nitrogen atom of the urea molecule) to form argininosuccinate (catalysed by argininosuccinate synthetase, ASS). The argininosuccinate is then cleaved to form arginine and fumarate (catalysed by argininosuccinate lyase, ASL), and the arginine is cleaved by arginase to form urea and ornithine (regenerating the ornithine for the next cycle).
The clinical importance of the urea cycle is underscored by the urea cycle disorders (UCDs) — a group of rare genetic disorders that are characterised by deficiencies in the enzymes of the urea cycle. The most common UCD is OTC deficiency (which accounts for approximately 50% of all UCDs), followed by CPS1 deficiency, ASS deficiency, ASL deficiency, and arginase deficiency. The UCDs present in the neonatal period with hyperammonemia (lethargy, poor feeding, vomiting, seizures, and coma within the first few days of life) or in later childhood or adulthood with recurrent hyperammonemia triggered by protein intake, illness, or stress. The treatment of UCDs involves dietary protein restriction (to reduce the ammonia burden), the administration of nitrogen scavengers (sodium phenylbutyrate and sodium benzoate, which provide alternative pathways for nitrogen excretion), and in severe cases, liver transplantation.
L-Ornithine Supplementation and Hyperammonemia
L-ornithine supplementation has been studied for its potential effects on blood ammonia levels, on exercise performance, and on sleep. For blood ammonia management, L-ornithine supplementation has been shown to reduce blood ammonia levels in people with hyperammonemia (including people with cirrhosis, with urea cycle disorders, and with inherited OTC deficiency) and to improve cognitive function in people with hepatic encephalopathy (a complication of cirrhosis in which ammonia accumulation impairs brain function, producing confusion, asterixis, and in severe cases, coma). A double-blind RCT in 60 patients with cirrhosis and hepatic encephalopathy found that L-ornithine supplementation at 5g twice daily (10g daily) for 2 weeks significantly improved cognitive function and reduced blood ammonia levels compared to placebo — with benefits that were apparent within the first 3 days of treatment. The mechanism of this ammonia-lowering effect is thought to involve the provision of additional ornithine substrate for the urea cycle, which increases the capacity of the cycle to clear ammonia.
Practical Application
For general L-ornithine supplementation, the evidence-based dose is 2-5g of L-ornithine daily from L-ornithine L-aspartate or L-ornithine hydrochloride. The primary clinical indications for ornithine supplementation are hyperammonemia (in people with urea cycle disorders or with cirrhosis and hepatic encephalopathy — at doses of 5-10g daily in divided doses), exercise performance (particularly for the reduction of ammonia accumulation during high-intensity exercise, where ammonia accumulation contributes to central fatigue), and sleep (where ornithine has been studied for its potential effects on the reduction of ammonia levels during sleep and on the improvement of sleep quality). Ornithine is generally well-tolerated with no significant adverse effects at doses up to 10g daily. For comprehensive nitrogen metabolism support, ornithine pairs well with arginine (which is the product of the arginase reaction and which can be used for the synthesis of nitric oxide), with the B-complex vitamins (which are required for the function of the urea cycle enzymes), with lactulose (which is the standard treatment for hepatic encephalopathy and which reduces ammonia absorption from the gut), and with the dietary restriction of protein (during acute hyperammonemia episodes).
Leave a Reply